# Strategic conclusion

Your thesis is viable, but the winning entry point should be narrower than **“an AI-first Appsilon.”**

One important update: Appsilon’s current positioning has moved well beyond a custom Shiny development shop with light validation. It now markets custom R/Python applications, GxP-ready statistical computing environments with ongoing validation refreshes, Axon.R for automated package validation, TealFlow for AI-assisted clinical-app generation, and BioVerse as a modular analytical platform. BioVerse is described as customer-owned and stack-agnostic, and Appsilon lists both Posit and Domino among its partnerships. Platform flexibility and a general ability to support validation therefore will not, by themselves, distinguish a new entrant. ([Appsilon][1])

The sharper opportunity is:

> **Become the accountable application partner for one category of regulated workflow—from process discovery through app development, validation, deployment, and continued operation.**

That is materially different from selling R/Python engineering hours. Your commercial flywheel would be:

> **Manual workflow → paid discovery → working app → validated release → managed validated state → portfolio app factory → platform**

The app is the wedge. Continuous assurance creates recurring revenue. Reusable workflow components and validation automation become the eventual software product.

---

# 1. Recommended positioning

## Category

I would call the category **regulated application engineering** or **validated analytical application development**.

A strong positioning statement would be:

> **We replace submission-critical Excel, SAS, and manual workflows with governed R and Python applications—built quickly, validated when required, and maintained as they change.**

That is stronger than:

* “We build Shiny apps.”
* “We are an AI-first development agency.”
* “We help life sciences modernize.”
* “We build GxP-ready software.”

Those descriptions emphasize either technology or generic capability. The customer is actually buying:

* Faster regulated decisions
* Fewer manual errors and reconciliations
* Shorter analytical or submission cycle times
* A system QA will authorize
* A reliable supplier that remains accountable after go-live

## AI should be the operating model, not necessarily the headline

Appsilon already markets one-week AI-accelerated prototypes and describes a method based on written standards and test specifications before coding. It also emphasizes human approval and audit records for regulated AI. Simply calling the company “AI-first” will not be durable differentiation. ([Appsilon][2])

Use AI aggressively behind the scenes for:

* Requirements drafting
* Process mapping
* Application scaffolding
* Test generation
* Traceability generation
* Change-impact analysis
* Validation-document assembly
* Code review and defect triage

But lead customer-facing messaging with the business outcome and regulated delivery model. A useful formulation is:

> **AI-accelerated delivery, human-accountable releases.**

---

# 2. Pick a narrow beachhead

## Recommended initial workflow family

My default recommendation is:

> **Submission-supporting analytical review and quality-control applications**

Examples include:

* Clinical data review and issue-management applications
* TFL, ADaM, SDTM, metadata, and submission-readiness QC
* Biomarker, pharmacokinetic, and pharmacodynamic review tools
* Cross-study data reconciliation
* Interactive statistical review applications
* Report-generation and approval workflows
* Controlled replacements for analytical spreadsheets and SAS macro chains

This is preferable to immediately replacing an EDC, LIMS, MES, QMS, or regulatory document-management system. You can sit above existing systems of record, solve a painful workflow, and demonstrate value without starting with a multi-year enterprise transformation.

For the first projects, emphasize **submission-supporting** rather than **submission-authoritative**. For example, build the review, reconciliation, QC, or decision-support layer before taking responsibility for the final authoritative analysis pipeline. That reduces initial validation risk and gives you time to mature your quality system.

## Second vertical

After three to five successful applications, expand into:

> **Laboratory and CMC analytical workflow applications**

Good targets include:

* Assay calculations and result review
* Sample and result reconciliation
* Method-transfer workflows
* Environmental-monitoring analytics
* Stability-data review
* Instrument-data aggregation
* Exception and deviation review
* Analytical-development decision support

Initially remain a workflow and review layer above the LIMS, ELN, SDMS, or instrument system rather than becoming the regulated source of record.

## Ideal first customer profile

The strongest early customer is likely to be:

* A clinical-stage or commercial biotech, specialty pharma, CRO, or CDMO
* Roughly 300–5,000 employees
* Existing R/Python, Domino, Posit, Databricks, or cloud investments
* A small software-engineering team relative to the number of analytical users
* Internal QA and validation resources that are overloaded
* A visible manual workflow tied to a study, submission, inspection, or laboratory milestone
* An executive or director-level business owner who controls a budget

Your initial buyer is often a Head or Director of Statistical Programming, Biometrics, Clinical Data Science, Digital Labs, Analytical Development, or R&D Data Products. Quality and IT will influence the purchase, but the economic buyer should be the owner of the broken workflow.

## Avoid these first

Do not begin with:

* Batch-release decisions
* Lab instrument control
* Autonomous AI making critical regulated decisions
* Enterprise-wide SAS migration
* A complete replacement for LIMS, MES, EDC, or Veeva
* A new organization-wide data platform
* Applications requiring dozens of integrations and sites
* Workflows without a committed process owner

The ideal first app has significant pain but a bounded validation surface.

---

# 3. Productize validation into three assurance levels

Not every app should receive the same packet. The offering should explicitly classify the application by intended use.

| Assurance level | Appropriate use                                                                                                          | Customer deliverables                                                                                                                                                                         |
| --------------- | ------------------------------------------------------------------------------------------------------------------------ | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| **Exploratory** | Research, visualization, hypothesis generation, non-regulated internal analysis                                          | Controlled source code, automated tests, architecture, deployment records, user documentation                                                                                                 |
| **Controlled**  | Business-critical decision support that does not directly create or approve regulated records                            | Intended use, requirements, risk assessment, traceability, test evidence, release record, access and change controls                                                                          |
| **Validated**   | GxP workflow, regulated record, critical calculation, formal approval, or submission-supporting use requiring validation | Validation plan, URS, risk and Part 11/Annex 11 assessments, specifications, IQ/OQ/PQ or equivalent assurance, traceability, deviations, validation summary, SOPs and ongoing validation plan |

This classification should be part of every paid discovery engagement. It prevents the company from over-validating low-risk apps and under-scoping critical ones.

For medical-device production and QMS software, FDA’s February 2026 CSA guidance expressly promotes a risk-based, least-burdensome approach and maintaining software in a state of control throughout its lifecycle. For pharmaceutical GMP applications, Annex 11 is more directly relevant: it calls for lifecycle traceability of user requirements, supplier assessment, appropriate testing, migration controls, and formal quality and performance assessment for bespoke or customized systems. ([U.S. Food and Drug Administration][3])

---

# 4. Phased business and offering roadmap

The following prices are planning ranges, not published market quotes.

| Phase                                |       Timing | Main customer promise                                                                                 | Productized offers                                                                                | Commercial model                                                                | Gate before advancing                                                                |
| ------------------------------------ | -----------: | ----------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------ |
| **0. Establish credibility**         |   0–6 months | Identify and prove the right application before a large commitment                                    | Workflow Modernization Scan; Validation Scope Assessment; App Prototype Sprint                    | $25K–$75K per engagement                                                        | Two paid discoveries, one lighthouse build, approved internal QMS                    |
| **1. Bespoke application wedge**     |  3–18 months | Replace one critical workflow with a production application                                           | Production App Build; Validated App Build; Existing App Validation Retrofit                       | $250K–$800K per app; $1M+ for complex apps                                      | Five production apps, three referenceable customers, repeatable architecture         |
| **2. Managed validated state**       |  9–30 months | Keep the app supported, current, and inspection-ready                                                 | AppCare; Continuous Validation; Managed Releases; Periodic Review                                 | $10K–$30K per month per material app                                            | 25%–35% recurring revenue; most release evidence automated                           |
| **3. App factory and solution kits** | 18–42 months | Deliver multiple apps from reusable, regulated building blocks                                        | Validated App Factory; Submission Review Workbench; Lab QC Workbench; Regulatory Evidence Cockpit | $750K–$2M annual factory retainers; implementation plus annual license for kits | Three workflow patterns each sold at least three times                               |
| **4. Application control plane**     | 30–60 months | Allow internal and external developers to build governed apps on a standard regulated delivery system | Regulated App Platform; Evidence Graph; App Catalog; Developer SDK; Deployment Connectors         | Approximately $200K–$750K ARR plus services                                     | External teams successfully deliver and maintain apps without your full project team |

These phases should overlap. You do not stop bespoke work when managed services launch; you use each implementation to strengthen the reusable system.

---

# 5. Phase 0: Establish credibility and find the lighthouse

## Offer 1: Workflow Modernization Scan

**Duration:** two to four weeks
**Planning price:** $25,000–$60,000

Deliverables:

* Current-state workflow map
* Systems and spreadsheet inventory
* Manual handoffs and failure points
* User and stakeholder map
* Intended-use statement
* Preliminary GxP and Part 11 applicability
* Ranked application backlog
* ROI model
* Recommended architecture and platform
* Prototype scope
* Fixed-range build estimate

This is a paid consulting product, not free presales. It separates serious buyers from companies merely exploring ideas.

## Offer 2: App Prototype Sprint

**Duration:** five to ten working days
**Planning price:** $20,000–$50,000

Deliverables:

* Working narrow application slice
* Synthetic, de-identified, or controlled client data
* One complete business path
* Preliminary requirements
* Initial automated tests
* Architecture recommendation
* Production and validation roadmap

The prototype should not be throwaway code. It should use the same repository structure, package conventions, testing patterns, and deployment approach as a production application.

## Internal capabilities required before the first validated build

You need a small but defensible supplier quality system covering:

* Software development lifecycle
* Document and record control
* Requirements and risk management
* Source control and code review
* Testing and release management
* Change control
* Incident and CAPA handling
* Employee training
* Supplier and subcontractor management
* Security and access management
* Backup, business continuity, and record retention

You also need a standard quality agreement, shared-responsibility matrix, validation templates, coding standards, and supplier-assessment packet.

Your first demonstration app should show both the product and the delivery system. A good demo would be a **submission-readiness review application** using public or synthetic CDISC-like data, with:

* Interactive data review
* Automated QC
* Role-based review and approval
* Requirement-linked E2E tests
* Traceability
* Release metadata
* A generated validation evidence bundle

---

# 6. Phase 1: Bespoke app delivery as the wedge

## Core offer: Production App Build

The non-GxP version includes:

* Process and product discovery
* UX and workflow design
* R/Python analytical logic
* Shiny, React, Streamlit, Dash, or another suitable UI
* Data connectors
* Automated unit, integration, and E2E tests
* Infrastructure and deployment configuration
* Monitoring and logging
* User training
* Production handover
* Hypercare

## Core offer: Validated App Build

The validated version adds:

* Intended-use and GxP classification
* Validation plan
* URS or controlled product backlog
* Functional and architectural specifications
* Process and technical risk assessment
* Part 11 and Annex 11 assessment where applicable
* Requirements-to-test traceability
* IQ/OQ/PQ or equivalent assurance
* Migration and reconciliation testing
* Security, access, audit-trail, and signature testing
* Deviation records
* Validation summary report
* SOPs and periodic-review plan
* QA support through final approval

Do not sell validation as an after-the-fact documentation add-on. It should be integrated into engineering from the first requirement.

## Additional wedge: Existing App Validation Retrofit

Many companies already have an R, Python, Shiny, Dash, or Streamlit app that is useful but cannot be approved for regulated use.

Offer a retrofit that includes:

* Code and architecture assessment
* Intended-use clarification
* Testability and data-integrity assessment
* Risk classification
* Missing control implementation
* Automated regression suite
* Traceability reconstruction
* Validation packet
* Controlled deployment
* Ongoing support proposal

This may close faster than a greenfield development project because the internal business champion already knows the app’s value.

## Recommended technical approach

Do not make “Shiny” the company category. Use:

* **R** where statistical and clinical programming ecosystems dominate
* **Python** where data engineering, machine learning, APIs, and broader software ecosystems are important
* **React or another full web framework** where workflows have complex UI and transactional behavior
* **Shiny or Streamlit** where analytical interactivity and speed matter more than complex workflow behavior

Keep calculations and business rules in independently tested R/Python packages or services rather than embedding all logic in the UI. That makes reuse, testing, validation, and migration easier.

Appsilon’s own open-source strategy is instructive: Rhino and Tapyr provide opinionated project structures, testing, modularity, CI/CD, and enterprise application patterns. Your equivalent reusable IP should begin as internal engineering infrastructure before becoming a public product. ([Appsilon][4])

---

# 7. Phase 2: Turn every deployed app into recurring revenue

## Offer: AppCare

AppCare is standard application support:

* Monitoring
* Incident response
* Defect correction
* Dependency and security updates
* Performance management
* User and admin support
* Small enhancement allowance
* Service reporting
* Backup and recovery support

## Offer: Managed Validated State

This is the more differentiated recurring service:

* Change-impact assessment
* Risk-based regression selection
* Automated evidence capture
* Requirements and traceability updates
* Controlled release records
* Platform and dependency release monitoring
* Supplier-change review
* Deviation and CAPA support
* Access-review support
* Audit-trail review support
* Periodic evaluation
* Backup and restore evidence
* Annual inspection-readiness package
* Customer audit support

A typical price could be **15%–25% of the original application build cost annually**, or approximately **$10,000–$30,000 per month per significant app**, depending on criticality and release volume.

The contract must define:

* Included releases
* Included enhancement capacity
* Response times
* Validation activities
* Audit-support hours
* Customer approval obligations
* Excluded major changes

Otherwise “continuous validation” can turn into unlimited development under a support fee.

## What to build internally during this phase

Create a **validation-as-code system** that maintains:

> requirement → risk → control → code component → test → result → release

For every release, it should automatically capture:

* Source commit
* Pull request and approvals
* Build identifier
* Container digest
* Dependency versions
* Infrastructure version
* Database schema
* Requirements affected
* Tests executed
* Results
* Deviations
* Security scans
* Reviewer and approver
* Deployment record

The output can still be rendered into the customer’s required Word, PDF, Veeva, Kneat, ValGenesis, or other validation-management format. The source of truth should be structured and machine-readable.

That system is the beginning of the eventual platform.

---

# 8. Phase 3: Move from custom projects to an app factory

Do not productize a workflow merely because one customer requested it. Wait until the same underlying process appears repeatedly.

A practical threshold is:

* At least three customers
* Similar users and business outcomes
* At least 60% common requirements
* At least 70% common technical components
* A repeatable validation strategy
* A buyer willing to pay recurring license or support fees

## Potential solution kits

### Submission Review Workbench

Reusable components could include:

* Study and dataset inventory
* SDTM/ADaM and metadata checks
* TFL and report review
* Discrepancy workflow
* Reviewer assignment
* Approval and audit trail
* Readiness dashboard
* Evidence export

### Lab Analytical Review Workbench

Reusable components could include:

* Data import from LIMS, ELN, SDMS, or files
* Calculation and data-quality rules
* Sample reconciliation
* Exception management
* Reviewer workflow
* Audit trail
* Report creation
* Method and version tracking

### Regulatory Evidence Cockpit

Reusable components could include:

* Requirement and evidence inventory
* Submission deliverable status
* Review and approval workflow
* Traceability
* Document and output QC
* Issues and decisions
* Release history

These should be sold as **80% prebuilt, 20% configured**, not as inflexible SaaS products.

## Offer: Validated App Factory

Rather than selling apps one at a time, sell annual capacity:

* Dedicated or shared engineering pod
* Quarterly app roadmap
* Standard design system
* Reusable regulated components
* Common data connectors
* Standard assurance process
* Managed releases
* Portfolio reporting

A planning price of **$750,000–$2 million annually** is plausible depending on team size and number of applications.

This is the point where you begin selling to a Head of Data Products, Digital Labs, Biometrics Platforms, or Enterprise Analytics rather than only individual project owners.

---

# 9. Phase 4: Build the platform—but build the right platform

Do not initially build another data lake, notebook platform, or general-purpose MLOps product. Domino, Posit, Databricks, Snowflake, Azure, and AWS already occupy those layers.

Domino can publish Shiny, Dash, Streamlit, and Flask applications while managing infrastructure, permissions, routing, identity, logs, and reproducible application snapshots. Domino also makes clear that GxP remains a shared-responsibility model in which customers are primarily responsible for how workloads are designed and managed. That is precisely the layer where your application and assurance system can add value. 

Your eventual platform should be a **regulated application control plane** that sits above existing data and compute platforms.

## Platform modules

### Application templates and SDK

* R/Shiny template
* Python/Shiny or Streamlit template
* React/API template
* Preconfigured testing
* Security and observability
* Deployment manifests
* Validation metadata

### Reusable regulated components

* Identity and role management
* Review and approval workflows
* Electronic-signature integration
* Reason-for-change capture
* Audit-event generation
* Record export
* Data lineage
* File ingestion and reconciliation
* Calculation verification
* Report generation
* Notification and escalation

### Evidence graph

* Requirements
* Risks
* Controls
* Tests
* Defects
* Releases
* Approvals
* Periodic reviews

### Continuous validation engine

* Change detection
* Impact assessment
* Regression selection
* Evidence generation
* Deviation workflow
* Release gate
* Periodic-review aggregation

### Deployment adapters

* Domino
* Posit Connect
* Databricks
* Kubernetes
* AWS, Azure, and GCP
* Customer-specific CI/CD systems

### Validation-system integrations

* Veeva
* Kneat
* ValGenesis
* Jira
* ServiceNow
* Customer QMS and document-management systems

You do not need to displace those systems. Push the generated evidence into the customer’s approved system of record.

## Platform trigger

Do not sell this as software until:

* Your own engineers use it on every project
* It has supported at least 10–15 deployed applications
* It has processed dozens of controlled releases
* Customers ask to let their internal developers use it
* The app teams can demonstrate materially faster releases and lower validation effort

Until then, it is proprietary delivery infrastructure—not a product.

---

# 10. Domino and platform-partnership strategy

Domino can be a valuable first channel, particularly given your relationship and interview experience. The partnership offer should be concrete:

## “Domino Regulated App Launch Pack”

A customer receives:

* One prioritized business workflow
* A production application deployed through Domino
* An approved project and environment structure
* Application identity and permission integration
* Reproducible builds and releases
* Audit and execution logging
* Automated test suite
* App-level validation strategy and evidence
* Operating procedures
* Managed support proposal

The positioning to Domino is:

> “You provide the governed data-science and application platform. We create the regulated business applications that drive adoption and keep them in an approved state.”

This can help Domino account teams convert platform capacity into visible business outcomes.

Do not become Domino-exclusive. The underlying architecture should support:

* Domino customers
* Posit customers
* Databricks customers
* Customer-managed Kubernetes
* Conventional cloud applications

Appsilon’s current platform positioning is itself modular, customer-owned, and deployable across clouds, so platform agnosticism is increasingly table stakes. ([Appsilon][5])

---

# 11. Go-to-market motion

## Land with a paid problem, not a broad transformation

The sales sequence should be:

1. Identify a critical spreadsheet, SAS, or manual workflow.
2. Sell the Workflow Modernization Scan.
3. Produce a working prototype.
4. Contract the production and validation engagement.
5. Attach Managed Validated State before go-live.
6. Identify two adjacent applications.
7. Convert the account to an App Factory relationship.
8. Introduce workflow kits and platform capabilities.

## Best trigger events

Prioritize accounts experiencing:

* A regulatory submission within 6–18 months
* A clinical study entering a more operationally complex stage
* A SAS-to-open-source initiative
* A new Domino, Posit, or Databricks deployment
* A validation or data-integrity finding
* A backlog of analytical applications
* Repeated errors or delays from spreadsheets
* A laboratory digitalization program
* An organizational move from outsourced to internal analytics

## Channel strategy

Develop four channel types:

1. **Platform vendors:** Domino, Posit, Databricks, Snowflake, cloud providers.
2. **Validation and quality consultancies:** Firms that understand CSV but cannot build high-quality analytical apps.
3. **CROs, CDMOs, and laboratory consultants:** Firms with domain access but limited software-product capability.
4. **Validation-management vendors:** Integrate with rather than initially compete against Veeva, Kneat, and ValGenesis.

## Content strategy

Appsilon has built credibility partly through case studies, open-source frameworks, technical resources, and detailed educational material. Your equivalent should be narrower and operational. ([Appsilon][1])

Strong initial content would include:

* “How to retire a regulated Excel workflow”
* “When does an analytical app need GxP validation?”
* “A reference architecture for validated R/Python applications”
* “From URS to automated E2E evidence”
* “How to validate a Shiny or Streamlit app”
* “Domino shared responsibility at the application layer”
* Public demonstration apps with downloadable evidence bundles

Open-source one or two genuinely useful components, but keep the evidence engine and reusable commercial workflow modules proprietary.

---

# 12. Initial organization

A first delivery pod could consist of:

| Role                                 | Initial staffing |
| ------------------------------------ | ---------------: |
| Founder / product and domain lead    |                1 |
| Senior R application engineer        |                1 |
| Senior Python or full-stack engineer |                1 |
| Platform / DevOps engineer           |            0.5–1 |
| Validation and quality lead          |            0.5–1 |
| UX/product designer                  |       Fractional |
| Independent quality reviewer         |       Fractional |

The founder should initially own:

* Process discovery
* Buyer relationships
* Intended-use definition
* Value and ROI case
* Partner relationships
* Final project accountability

Do not outsource the validation lead or product-discovery role entirely. They are central to the differentiation.

Engineering can eventually use a blended onshore/nearshore delivery model, but senior customer-facing product, architecture, and quality leadership should remain close to the customer.

---

# 13. Economics and operating targets

These are reasonable internal targets rather than market benchmarks.

| Stage                         |        Gross-margin target | Recurring-revenue target |
| ----------------------------- | -------------------------: | -----------------------: |
| First bespoke projects        |           30%–40% realized |                  10%–15% |
| Repeatable app delivery       |                    40%–50% |                  20%–30% |
| Managed validated state       |                    45%–60% |                  30%–45% |
| Solution kits and app factory |                    50%–65% |                  40%–60% |
| Mature platform               | 75%+ software gross margin |                     60%+ |

To protect early margins:

* Require paid discovery before fixed-price builds.
* Define the number of interfaces, roles, requirements, migrations, and test cycles.
* Put customer review deadlines in the contract.
* Separate enhancements from validation maintenance.
* Price initial projects to a modeled 40%–45% gross margin because overruns will reduce realized margin.
* Retain ownership of generic components, validation automation, templates, and workflow accelerators.
* Let customers own or receive a perpetual license to customer-specific code and validation records.
* Deploy into customer-owned infrastructure whenever practical.

---

# 14. What to copy from Appsilon—and where to depart

## Copy

* Services financing reusable intellectual property
* Strong specialization in life-sciences workflows
* Customer-owned deployments
* Open-source credibility
* Platform partnerships
* Case-study and educational-content marketing
* Opinionated engineering templates
* Multiple entry offers, from prototype through platform

## Deliberately depart

* **Narrower first workflow:** Become known for one high-value regulated process.
* **Validation at the application level:** Not only infrastructure or package validation.
* **Managed validated state as standard:** Attach recurring assurance to every important deployment.
* **Business-process accountability:** Own discovery and adoption, not just engineering.
* **Platform independence:** Domino-ready, Posit-ready, and cloud-ready.
* **Measured outcomes:** Cycle time, error reduction, validation effort, release frequency, and user adoption.
* **No Shiny-only identity:** Select the right R, Python, and web architecture for the workflow.
* **Structured evidence as the moat:** Documents are generated views of the evidence graph rather than the primary system of record.

---

# 15. Concrete first 90 days

## Days 1–30

* Select one beachhead: submission review and QC is my default.
* Conduct 15–20 structured interviews with former GSK contacts, biotech leaders, QA, and platform vendors.
* Define the three assurance levels.
* Draft the internal SDLC and quality procedures.
* Build the shared-responsibility matrix and supplier-assessment package.
* Design the demonstration application.

## Days 31–60

* Build the demo application using the same reference architecture intended for client work.
* Generate the first automated requirements, traceability, test, and release bundle.
* Develop the Workflow Modernization Scan and Prototype Sprint sales materials.
* Begin conversations with Domino, Posit, and two validation consultancies.
* Identify 30 target accounts and specific trigger events.

## Days 61–90

* Sell two paid discovery projects.
* Convert one into a lighthouse production build.
* Structure the lighthouse contract with an attached managed-service option.
* Capture baseline metrics before development begins.
* Publish the first reference architecture and regulated-app guide.
* Start building the internal evidence graph from the lighthouse engagement.

---

# Recommended offering architecture

The cleanest customer-facing portfolio is:

1. **WorkflowScan** — identify the workflow, ROI, intended use, and validation scope.
2. **AppSprint** — prove the narrowest useful application in one to two weeks.
3. **ProductionBuild** — engineer and deploy the production application.
4. **ValidatedBuild** — produce the application and complete intended-use validation evidence.
5. **AppAssure** — maintain, release, review, and keep the app in a validated state.
6. **AppFactory** — deliver and operate a portfolio of regulated applications.
7. **ControlPlane** — allow customer and partner developers to build on your governed delivery and evidence system.

The core strategic sentence is:

> **Land with one critical spreadsheet replacement, retain the customer by maintaining its validated state, expand into an app portfolio, and only then expose the delivery system as a platform.**

[1]: https://www.appsilon.com/ "Open Source, Done Right for Pharma | Appsilon"
[2]: https://www.appsilon.com/services/ai-for-pharma "AI for Pharma — Validated AI Systems | Appsilon"
[3]: https://www.fda.gov/media/188844/download "Computer Software Assurance for Production and Quality Management System Software"
[4]: https://www.appsilon.com/rhinoverse "Rhinoverse: Open-Source R Packages for Enterprise Shiny Apps"
[5]: https://www.appsilon.com/bioverse "BioVerse — Pharma Analytics Platform for Life Sciences | Appsilon"
